Francisco Trust Under Agreemen Sells 15,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $2.01, for a total value of $30,150.00. Following the transaction, the insider owned 3,375,664 shares in the company, valued at $6,785,084.64. This trade represents a 0.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

DYAI stock opened at $0.94 on Monday. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International Inc. has a 1-year low of $0.65 and a 1-year high of $1.35. The firm has a fifty day moving average price of $0.77 and a two-hundred day moving average price of $0.83. The firm has a market cap of $34.27 million, a price-to-earnings ratio of -4.09 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. Research analysts predict that Dyadic International Inc. will post 0.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dyadic International has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds have recently added to or reduced their stakes in the stock. Marathon Capital Management acquired a new position in shares of Dyadic International during the third quarter valued at $41,000. Bank of America Corp DE grew its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the third quarter worth about $190,000. Geode Capital Management LLC increased its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Finally, Apis Capital Advisors LLC acquired a new stake in shares of Dyadic International in the 3rd quarter worth about $1,817,000. 27.95% of the stock is currently owned by institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.